An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at ...

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients with intermediate-risk disease, according to study results presented at the ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

Robert De Niro, Warren Buffett and Ben Stiller had prostate cancer, detected at an early-enough stage to allow for recovery. Their treatments included surgery and radiation -- which may sometimes ...

March 4, 2010 — The results of a landmark study often represent the definitive word clinically. For the landmark Radiation Therapy Oncology Group (RTOG) 94-08 study, which evaluated short-term hormone ...

Adding external-beam radiation to brachytherapy does not improve 5-year freedom from progression (FFP) for men with intermediate-risk prostate cancer, but it does increase treatment toxicity. The ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

SAN ANTONIO, October 22, 2018 -- Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, ...

Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond ...